Amicus Therapeutics Inc

Amicus Therapeutics — SPAC Merger (September 2021)

17 slides from Amicus Therapeutics's SPAC merger presentation, Sep 29, 2021

  1. Slide 1: Amicus Launches Next-Generation Genetic Medicine Company

    Amicus Launches Next - Generation Genetic Medicine Company Conference Call & Webcast September 29, 2021

  2. Slide 2: Forward-Looking Statements

    2 Forward - Looking Statements This p resentation contains “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 relating to the business combination, development of Caritas’ product candidates, preclinical and clinical development of our product c

  3. Slide 3: Disclaimer

    3 Disclaimer Participants in the Solicitation ARYA IV and its directors, executive officers, other members of management, and employees, under SEC rules, may be deemed to be participants in the solicitation of proxies of ARYA IV’s shareholders in connection with the business combination . Investors

  4. Slide 4: Executive Summary

    4 Executive Summary ▪ AT - GAA NDA/BLA accepted for review: respective PDUFA action dates of May 29, 2022 and July 29, 2022 ▪ Amicus gene therapy programs, technologies, IP, and relationships to form new company: Caritas Therapeutics ▪ Caritas to be acquired by ARYA IV, a special purpose acquisition

  5. Slide 5: Amicus has built a leading fully integrated, global rare disease biotechnology company

    5 Amicus has built a leading fully integrated, global rare disease biotechnology company Gene Therapy PLATFORM Protein Engineering & Glycobiology $383M Cash as of 6 /30/21 Two Clinical - Stage Gene Therapies AT - GAA Registration in Pompe Disease GLOBAL COMMERCIAL ORGANIZATION World Class BIOLOGICS

  6. Slide 6: Operating from Position of Strength

    6 Operating from Position of Strength Galafold ® continues to exceed expectations in Fabry disease FY16 FY17 FY18 FY19 FY20 FY21 $37M $91M $261M FY21 Rev. Guidance $300M - $315M $182M $5M Two lead programs each with potential $500M - $1B peak sales opportunity AT - GAA submissions in Pompe disease a

  7. Slide 7: Poised to Unlock Value

    7 Poised to Unlock Value Significant but unrecognized value created across Amicus' leading rare disease gene therapy pipeline and cutting - edge next - generation platform technologies and partnerships DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY Batten Franchise CLN6 Batten Disease CLN3 Batte

  8. Slide 8: Simplified Transaction Structure

    8 Simplified Transaction Structure (1) Amicus intends to launch Caritas as a next - generation genetic medicine company • Combining Amicus's gene therapy business with ARYA IV, a special purpose acquisition company (SPAC) • Caritas is carved out of Amicus, retaining a collaboration with the Perelman

  9. Slide 9: Strategic Rationale

    9 Strategic Rationale We believe this transaction will generate greater value for all stakeholders, significant therapeutic advancement, and result in benefits to the stand - alone companies 1 2 3 4 6 Enhancing the ability of both Amicus and Caritas to meet the unmet needs of patients living with r

  10. Slide 10: Transforming for the Future

    10 Transforming for the Future • Amicus remains a global, patient - dedicated biotechnology company developing and delivering novel high - quality medicines for people living with rare diseases • Focus will be to grow its leadership position across the Company’s two lead indications of Fabry disease

  11. Slide 11: Strengthening the Financial Profile of Amicus

    11 Strengthening the Financial Profile of Amicus • Increases focus on commercial success of Galafold and AT - GAA – Aims at maximizing patient access to Galafold and AT - GAA, each with $500M - $1B peak sales opportunity • Strengthens the financial outlook of Amicus – Reiterating financial guidance

  12. Slide 12: Harnessing the Power of Genetic Medicine

    12 Harnessing the Power of Genetic Medicine The mission of Caritas is to transform the lives of children and adults living with rare genetic diseases through advanced protein engineering and innovative vector technologies Diversified portfolio of clinical and preclinical rare disease development pro

  13. Slide 13: Three Strategic Value Drivers

    13 Three Strategic Value Drivers Deep science in protein engineering driving a robust pipeline supported by industry - leading partnerships ▪ Modern protein engineering platforms generating bespoke solutions ▪ Engineered proteins and transgenes for enhanced expression, cross correction, targeting an

  14. Slide 14: Co-Development and Commercialization Agreement

    14 Co - Development and Commercialization Agreement New Amicus and Caritas collaboration around genetic medicine for Fabry and Pompe diseases • Differentiated gene therapy approach for greater potency and optimized cross correction through transgene engineering for stability and targeting – Fabry di

  15. Slide 15: Planning for a Seamless Evolution in Leadership

    15 Planning for a Seamless Evolution in Leadership • Amicus Chairman & CEO for 15+ years • Co - founder, President and CEO of Novazyme Pharmaceuticals (acquired by Genzyme in 2001) • Member of the Intellia and Entrada Therapeutics Board of Directors • B.S. from Georgetown University, J.D. from the U

  16. Slide 16: Transaction Summary

    16 Transaction Summary Unlocking value by allowing two stand - alone companies to realize their full potential Transaction Details • Business combination of the Amicus Gene Therapy Business with ARYA IV, a SPAC, resulting in the launch of Caritas Therapeutic s, an independent, publicly traded c ompa

  17. Slide 17: Thank You

    Thank You “Our passion for making a difference unites us” - Amicus Belief Statement Exhibit 99.3 Operator: Thank you for joining our call today. In this call we’ll be discussing information contained in our press release issued today. Before we discuss what we believe is a very exciting announcement

Amicus Therapeutics — SPAC Merger (September 2021) on 6ix